686725-74-6

Basic information

• Product Name: 5-(4-bromophenyl)-3-(2-furyl)-3,4-dihydropyrazole-2-carbothioamide
• CAS NO: 686725-74-6
• Molecular Formula: C₁₄H₁₂BrN₃OS
• Molecular Weight: 350.2336
• Mol File: 686725-74-6.mol

Chemical Properties

• Boiling Point: 468.42°C at 760 mmHg
• Flash Point: 237.092°C
• Density: 1.648g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.728
• CAS DataBase Reference: 5-(4-bromophenyl)-3-(2-furyl)-3,4-dihydropyrazole-2-carbothioamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-bromophenyl)-3-(2-furyl)-3,4-dihydropyrazole-2-carbothioamide(686725-74-6)
• EPA Substance Registry System: 5-(4-bromophenyl)-3-(2-furyl)-3,4-dihydropyrazole-2-carbothioamide(686725-74-6)

Safety Data

• Hazardous Substances Data: 686725-74-6(Hazardous Substances Data)

Upstream product

• 36715-58-9 (E)-1-(4-bromophenyl)-3-(furan-2-yl)-2-propen-1-one 
• 79-19-6 thiosemicarbazide 
• 99-90-1 para-bromoacetophenone 
• 98-01-1 furfural 

Downstream Products

• 1386394-40-6 2-(3-(4-bromophenyl)-5-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one 
• 1386394-28-0 2-(3-(4-bromophenyl)-5-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole 
• 1386394-31-5 2-(3-(4-bromophenyl)-5-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-methoxyphenyl)thiazole 

Relevant articles and documents

Discovery and modification of sulfur-containing heterocyclic pyrazoline derivatives as potential novel class of β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors

A series of sulfur-containing heterocyclic pyrazoline derivatives (C1-C18; D1-D9) have been synthesized and purified (all are new except one) to screen for FabH inhibitory activity. Compound C14 showed the most potent biological activity against Escherich

Novel 3,3a,4,5,6,7-Hexahydroindazole and Arylthiazolylpyrazoline derivatives as Anti-inflammatory Agents

A novel series of 7-benzylidene-3,3a,4,5,6, 7-hexahydro-3-phenyl-2H-indazole substituted at the 2-position were synthesized. The reaction of 2,6-bis-benzylidenecyclohexanone (1) with thiosemicarbazide in the presence of NaOH afforded a mixture of the 3-H, 3a-H trans 2 and cis 2a diastereoisomers which have been separated by fractional recrystallization. Interaction of the first intermediate 2 with substituted phenacyl bromides, aromatic aldehydes and chloroacetic acid in presence of a mixture of acetic acid and acetic anhydride, and 2,3-dichloroquinoxaline yielded the corresponding 7-benzylidene-3,3a,4,5,6,7-hexahydro-3-phenyl-2H-indazole derivatives substituted at the 2-position with 4-aryl-2-thiazolyl 3 a, b, 5-arylidene-4,5-dihydro-4-oxo-2-thiazolyl 4a, b and thiazolo[4,5-b]quinoxalin-2-yl 5, respectively. Moreover, the other intermediates 3,5-diaryl-1-thiocarbamoyl-2-pyrazolines 7 a-d were reacted with the previously-mentioned reagents and gave the corresponding 3,5-diaryl-1-(4-aryl-2-thiazolyl)-2-pyrazolines 8 a-h, 3,5-diaryl-1-(5-arylidene-4,5-dihydro-4-oxo-2-thiazolyl)-2-pyrazolines 9 a-d and 3,5-diaryl-1-(thiazolo[4,5-b]quinoxalin-2-yl)-2-pyrazoline derivatives 10 a, b, respectively. Some of the newly prepared compounds were subjected to evaluation for their anti-inflammatory activity. The structures of the new compounds were confirmed by elemental analyses as well as 1H-NMR, IR, and MS data.